^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
rocapuldencel-T (CMN-001)
i
Other names: CMN-001, AGS-003 , AGS-003-LNG
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CoImmune, SCM Lifescience
Drug class:
Immunostimulant
Related drugs:
over1year
A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma. (PubMed, Hum Vaccin Immunother)
The synergy between CMN-001 and everolimus observed in the phase 3 study provides an opportunity to design a phase 2b study building on the mechanism of action of CMN-001 and underlying immune and clinical outcomes revealed in the earlier studies. The design of the phase 2b study combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus in poor-risk mRCC subjects.
Review • Journal • Metastases
|
everolimus • Lenvima (lenvatinib) • rocapuldencel-T (CMN-001)
over4years
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, GU Research Network, LLC | N=20 --> 0 | Recruiting --> Withdrawn
Clinical • Enrollment change • Trial withdrawal
|
CD8 (cluster of differentiation 8)
|
cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • rocapuldencel-T (CMN-001)
Share via
